Oncurious, along with BioInvent International and Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), has begun a Phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of TB-403 for the treatment of relapsed or refractory medulloblastoma.

Medulloblastoma is a rare, life-threatening brain tumour that mainly affects children.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The TB-403, co-developed by Oncurious and BioInvent, is a humanised monoclonal antibody against placental growth factor (PlGF), which is expressed in several types of cancer, including medulloblastoma.

Oncurious noted that treatment with TB-403 in pre-clinical models for medulloblastoma has showed positive effects on tumour growth and survival.

"We are hopeful that this novel antibody, targeting placental growth factor, will provide an improved treatment option for children afflicted with this lethal brain tumour."

In previous clinical trials, TB-403 has been shown to have a favourable safety profile in healthy volunteers and adult patients with various types of solid tumours.

See Also:

US-based NMTRC is a collaboration of 25 US academic medical centres, teaching hospitals and other entities, established with the aim of facilitating and conducting collaborative research activities and investigations of new treatments for neuroblastoma, medulloblastoma and other pediatric cancers, and is the key clinical trial partner for this Phase I/IIa study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study intends to enrol a minimum of 27 patients, with first results expected to be reported next year.

Oncurious executive chairman Patrik De Haes said: "We are pleased to announce the initiation of this important Phase I/IIa study with TB-403, a key corporate milestone for Oncurious.

"Given the encouraging pre-clinical data generated with TB-403 in Leuven and Boston, we are hopeful that this novel antibody, targeting placental growth factor, will provide an improved treatment option for children afflicted with this lethal brain tumour."